Investors can apply for the Aptus Pharma IPO through their broker’s online trading platform or supported financial applications. The process involves logging into the trading account, navigating to the IPO section, and selecting Aptus Pharma IPO from the active list. Applicants then need to enter the number of lots they wish to apply for within the given price band, provide their UPI ID for payment, and confirm the details before submission. The UPI mandate must be approved before the cut-off time to ensure the application is valid.
For complete details on this public offering, visit the Aptus Pharma IPO page on our website.
Aptus Pharma IPO Application Process
The Aptus Pharma IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using the broker's app or website.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Aptus Pharma IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (minimum lot size: 2000 shares) within the price band of ₹65 to ₹70 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for Allotment
Submit the application and monitor the allotment status to check if shares have been allocated to you.
Additional Read: Aptus Pharma IPO Investment Guide: Objectives & Opportunities
About Aptus Pharma IPO: Overview and Key Facts
Aptus Pharma Ltd, incorporated in 2010, is a pharmaceutical company engaged in the marketing and distribution of finished formulations across multiple therapeutic categories. Its portfolio includes medicines for gastrointestinal care, pain management, antibiotics, cardiology, diabetes, neuropsychiatry, dental, nutraceuticals, injectables, and general wellness. The business operates under four distinct divisions: Aptus Pharma for acute therapies, Aptus CD Care for chronic conditions, Aptus Wellcare for nutraceutical and wellness products, and Aptus Global for overseas markets.
The company does not own manufacturing facilities but operates through a contract manufacturing model. It collaborates with seven partner units via a combination of formal agreements and purchase order-based arrangements. This approach enables Aptus Pharma to offer a wide variety of dosage forms such as tablets, capsules, softgels, syrups, and suspensions. As of March 2025, it managed 194 formulations in more than eleven therapeutic areas, supported by a warehousing setup and an extensive distribution network.
The IPO is being launched to fund capital expenditure for office premises, furniture, and industrial racks, as well as to support working capital needs and general corporate purposes. The issue size is 18,60,000 shares, aggregating up to ₹13.02 crore, with shares proposed to be listed on SME BSE. The offering provides a closer look at how Aptus Pharma aims to strengthen its operational base while maintaining an asset-light business model through its distribution-driven strategy.
To check your application status, visit the Aptus Pharma IPO Allotment Status page on Bajaj Broking’s website.